.
Further to my rant above, I am a bit concerned that if we are to get back to (say) 40 cents per share, our market cap will need to go to around AU$240mill ... now if all the market will pay us for a magnificent product line such as Cardiocell and Vascucell is around AU$30mill tops then how the hell are we going to get AU$ 200 mill + out of a product which is an add-on to existing products in the TAVR space?
Fantasy is fine for some, but I stand to be convinced of the fundamentals of this strategy. I see maybe 2 years ahead before we are in real trouble again.
.
Ann: Appendix 4C - quarterly, page-24
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.20 |
Change
0.050(0.33%) |
Mkt cap ! $292.1M | |||
| Open | High | Low | Value | Volume |
| $15.35 | $15.35 | $15.00 | $20.85K | 1.367K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 132 | $15.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.30 | 290 | 2 |
View Market Depth
| Last trade - 10.50am 31/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |